Enable AccessibilityEnable Accessibility

Takeda Further Expands Help At Hand Patient Assistance Program in U.S.

June 15, 2018

Deerfield, Ill., June 15, 2018 – Takeda today announced its U.S. Business Unit will further expand its patient assistance program to help more patients access their medications. 

Help At Hand provides assistance for people to access their prescribed medications after all other options have failed to meet their needs. Under the expanded program, Takeda will allow individuals with incomes at 500 percent of the Federal Poverty Level (FPL) to apply for its free medicine program which offers 11 currently marketed prescription drugs from Takeda for free to qualifying patients.

“Ensuring patients have access to the medicines they need is a top priority for Takeda. We recognize that some patients continue to face real challenges in affording their medicines,” said Amanda Valyer, Sr. Patient Assistance and Operations Manager, Takeda Pharmaceuticals U.S.A., Inc. “By broadening the eligibility criteria for our patient assistance program, we can support many more patients.”

Formerly offered at 400 percent of the FPL, this expansion will mean an individual with an income at or below $60,700, or a family of four with a household income of about $125,500 may qualify for its free prescription drug program. 

For information please visit www.TakedaHelpAtHand.com.

  • The Help At Hand program offers 11 currently-marketed Takeda pharmaceutical products. This expansion of the Help At Hand program does not include Takeda Oncology products which have dedicated patient assistance programs.
  • The 2018 U.S. Federal Poverty Level guidelines can be found here: https://aspe.hhs.gov/poverty-guidelines

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries. For more information, visit https://www.takeda.com/newsroom/.

Takeda Pharmaceuticals U.S.A., Inc. is located in Deerfield, Ill., and is the U.S. marketing and sales organization of Takeda Pharmaceutical Company Limited.

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Pharmaceuticals U.S.A., Inc. is available through its website, www.takeda.us.


Justine Grosvenor
Takeda Pharmaceuticals U.S.A., Inc.
TEL: 224-554-1583
[email protected]